254 related articles for article (PubMed ID: 23591198)
1. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
[TBL] [Abstract][Full Text] [Related]
2. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
Usul Afsar Ç; Karabulut M; Karabulut S; Alis H; Gonenc M; Dagoglu N; Serilmez M; Tas F
J Infect Chemother; 2017 Apr; 23(4):196-200. PubMed ID: 28087305
[TBL] [Abstract][Full Text] [Related]
3. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
9. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
Brody JR; Witkiewicz AK; Yeo CJ
Adv Surg; 2011; 45():301-21. PubMed ID: 21954696
[No Abstract] [Full Text] [Related]
10. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
[TBL] [Abstract][Full Text] [Related]
11. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
[TBL] [Abstract][Full Text] [Related]
12. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Boeck S; Wilkowski R; Bruns CJ; Issels RD; Schulz C; Moosmann N; Laessig D; Haas M; Golf A; Heinemann V
Oncology; 2007; 73(3-4):221-7. PubMed ID: 18424886
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
Ma G; Sun Y; Fu S
Int J Clin Exp Pathol; 2015; 8(10):13284-8. PubMed ID: 26722531
[TBL] [Abstract][Full Text] [Related]
15. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
[TBL] [Abstract][Full Text] [Related]
18. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
[TBL] [Abstract][Full Text] [Related]
19. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Kourie HR; Gharios J; Kattan J
Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
[No Abstract] [Full Text] [Related]
20. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
